Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Thomas

Showing results (491-500 of 792) with videos related to

Pageof 80
Sort By:
Vaccine|March 5, 2023
Coverage survey and lessons learned from a pre-emptive cholera vaccination campaign in urban and rural communities affected by landslides and floods in Freetown Sierra LeoneMarcello Gelormini, Marissa Gripenberg, Dennis Marke, et al.
Nature Communications|February 4, 2026
Decoding efficacy and resistance space at a drug binding siteSimone Altmann, Cesar Mendoza-Martinez, Melanie Ridgway, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2025
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)Alfredo Addeo, Daniel Dietrich, Nicolas Mach, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 15, 2024
The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancerSarah Richtmann, Sebastian Marwitz, Thomas Muley, et al.
BMC Cancer|September 24, 2022
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trialFarastuk Bozorgmehr, Petros Christopoulos, Inn Chung, et al.
Oncology Research and Treatment|December 3, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung CancerMaximilian Webendörfer, Sophie Heinzen, Christine Sibbert, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2023
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adultsYizhe Chen, David Wyatt, Massimo Attanasio, et al.
European Journal of Medical Research|August 15, 2015
Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomasJuliane Rieber, Julian Schmitt, Arne Warth, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2021
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approachKen Ogasawara, Rebecca N Wood-Horrall, Mark Thomas, et al.
Histopathology|August 7, 2018
Deficient CD247 expression is a typical histopathological characteristic of thymomas with cortical featuresPetros Christopoulos, Inn Chung, Farastuk Bozorgmehr, et al.
Pageof 80

Showing results (491-500 of 792) with videos related to

Sort By:
Pageof 80
Vaccine|March 5, 2023
Coverage survey and lessons learned from a pre-emptive cholera vaccination campaign in urban and rural communities affected by landslides and floods in Freetown Sierra LeoneMarcello Gelormini, Marissa Gripenberg, Dennis Marke, et al.
Nature Communications|February 4, 2026
Decoding efficacy and resistance space at a drug binding siteSimone Altmann, Cesar Mendoza-Martinez, Melanie Ridgway, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2025
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)Alfredo Addeo, Daniel Dietrich, Nicolas Mach, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 15, 2024
The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancerSarah Richtmann, Sebastian Marwitz, Thomas Muley, et al.
BMC Cancer|September 24, 2022
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trialFarastuk Bozorgmehr, Petros Christopoulos, Inn Chung, et al.
Oncology Research and Treatment|December 3, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung CancerMaximilian Webendörfer, Sophie Heinzen, Christine Sibbert, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2023
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adultsYizhe Chen, David Wyatt, Massimo Attanasio, et al.
European Journal of Medical Research|August 15, 2015
Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomasJuliane Rieber, Julian Schmitt, Arne Warth, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2021
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approachKen Ogasawara, Rebecca N Wood-Horrall, Mark Thomas, et al.
Histopathology|August 7, 2018
Deficient CD247 expression is a typical histopathological characteristic of thymomas with cortical featuresPetros Christopoulos, Inn Chung, Farastuk Bozorgmehr, et al.
Pageof 80